Bench-to-bedside review: the gut as an endocrine organ in the critically ill.
In health, hormones secreted from the gastrointestinal tract have an important role in regulating gastrointestinal motility, glucose metabolism and immune function. Recent studies in the critically ill have established that the secretion of a number of these hormones is abnormal, which probably contributes to disordered gastrointestinal and metabolic function. Furthermore, manipulation of endogenous secretion, physiological replacement and supra-physiological treatment (pharmacological dosing) of these hormones are likely to be novel therapeutic targets in this group. Fasting ghrelin concentrations are reduced in the early phase of critical illness, and exogenous ghrelin is a potential therapy that could be used to accelerate gastric emptying and/or stimulate appetite. Motilin agonists, such as erythromycin, are effective gastrokinetic drugs in the critically ill. Cholecystokinin and peptide YY concentrations are elevated in both the fasting and postprandial states, and are likely to contribute to slow gastric emptying. Accordingly, there is a rationale for the therapeutic use of their antagonists. So-called incretin therapies (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) warrant evaluation in the management of hyperglycaemia in the critically ill. Exogenous glucagon-like peptide-2 (or its analogues) may be a potential therapy because of its intestinotropic properties.
Deane
Adam
A
Royal Adelaide Hospital, Department of Intensive Care, North Terrace, Adelaide 5000, South Australia. adam.deane@adelaide.edu.au
Chapman
Marianne J
MJ
Fraser
Robert J L
RJ
Horowitz
Michael
M
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D002766:Cholecystokinin / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D016638:Critical Illness; D004703:Endocrine System / Q000187:drug effects / Q000378:metabolism; D041981:Gastrointestinal Tract / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007408:Intestinal Absorption / Q000187:drug effects / Q000502:physiology; D019894:Peptide YY / Q000378:metabolism / Q000627:therapeutic use; D019095:Point-of-Care Systems / Q000639:trends*
D001786:Blood Glucose; D019894:Peptide YY; D002766:Cholecystokinin